Summary We analysed 78 carcinomas of the lung for allelic losses on chromosome 1 Oq. The tumours were of different stage and grade and comprised 22 small-cell lung carcinomas (SCLC), 40 squamous cell carcinomas (SCC), 11 adenocarcinomas, four large-cell carcinomas and one carcinoid. They were investigated by six polymorphic markers located between 1 0q21 and 1 Oqter. We observed a high incidence of loss of heterozygosity (LOH) in SCLC (91%) and metastatic SCC (56%). Non-metastatic SCC showed deletions in three cases (14%) and no LOH was found in the other types of non-small-cell lung cancer. The statistical analysis indicated that the presence of LOH correlated significantly with advanced tumour stages in the entire collective and in particular within the SCLC and SCC subgroups. For SCC, a positive association was found between LOH and metastases formation, while in SCLC the number of non-metastatic tumours was too small for a final conclusion. Whereas SCLC was frequently characterized by multiple allelic losses, suggesting the deletion of the entire chromosomal arm, SCC showed interstitial imbalances. A high incidence of allelic loss was observed between the markers D10S677 and D10S1223. The analysis of five informative cases suggested the presence of two non-overlapping regions between the loci Dl 0S677/D10S1237 and Dl OS1213/Dl OS1223. In SCLC, we did not find mutations in the putative tumour-suppressor gene MXI1. The data indicate that LOH on chromosome 10q is associated with tumour progression in SCC and SCLC. Thus it may become a useful genetic marker in the assessment of the malignant potential of these tumour types.
Cancer of the lung has the highest incidence of all solid tumours and is the leading cause of cancer deaths (Pisani et al, 1993) . The major histopathological distinction of clinical relevance is between small-cell and non-small-cell lung carcinomas. SCLC has to be considered a systemic disease at the time of diagnosis as the majority of cases show early metastases formation. It is preferentially treated by chemotherapy and radiotherapy. The NSCLC consist mainly of three subtypes, i.e. adenocarcinomas, squamous cell carcinomas (SCC) and large-cell carcinomas (LCLC) . The significance of the latter group is unclear as LCLC frequently show features of either adenocarcinomas or SCC; they can usually be attributed to these two subgroups by ultrastructural examination. There is a prevailing pattern of distribution within the lung. Whereas adenocarcinomas tend to be located in the periphery, SCC and SCLC arise preferentially from the central bronchi near the hilus.
A distinct histopathological diagnosis with far-reaching clinical consequences, i.e. possibly curative operation vs palliative chemotherapy, is often complicated by the morphological heterogeneity that occurs in up to 30% of cases (Muller and FisselerEckhoff, 1989) . The tumour heterogeneity is reflected in the World Health Organization (WHO) classification by the composite entities such as combined oat cell carcinoma (SCLC with NSCLC component) and adenosquamous carcinoma (WHO, 1982) . Similar to the pattern of distribution, SCLC does coincide more often with SCC than with adenocarcinoma (Hirsch et al, 1983) . As the morphological diagnosis may be biased by the tumour heterogeneity, additional criteria are necessary for the characterization of lung carcinomas.
Genetic lesions form the basis of tumour initiation and progression. The assessment of allelic loss hinting at loci of putative tumour-suppressor genes has proven valuable in the genetic characterization of lung carcinomas (Tsuchiya et al, 1992; Gazdar et al, 1994; Sato et al, 1994; Thiberville et al, 1995; Neville et al, 1996) . We have shown previously that SCLC and a subset of SCC is characterized by DNA loss on chromosome lOq (Petersen et al, 1997a and b; Schwendel et al, 1997) . Allelotype studies in other tumour types have suggested that chromosome lOq harbours at least one gene that is important in the tumour progression of meningioma, prostate cancer and brain tumours (von Deimling et al, 1992; Rempel et al, 1993; Gray et al, 1995) . As chromosome lOq loss was the second most frequent finding in SCLC after 3p deletions, which are implicated in early tumour development (Bockmuhl et al, 1996; Califano et al, 1996) , we speculated that this lesion may contribute particularly to the highly malignant phenotype of SCLC and other types of human lung carcinomas.
To test this hypothesis we investigated lung tumours of different histological type, grade and stage for the presence of allelic loss on chromosome lOq. Six polymorphic markers at the loci D1OS677, DIOS1237, DOS1213, DOS1223, DIOS169 and DlOS212 were used to analyse paired samples of tumour and normal DNA of 78 lung cancer patients. The collective was subdivided into four groups that consisted of SCLCs, non-metastatic SCC, metastasizing SCC 10q loss in lung cancer 271 In addition, we investigated the SCLCs for mutations in the helix-loop-helix and leucine-zipper exons of the MXI1 gene, which negatively interacts with the myc protooncogene and has been suggested as a tumour-suppressor gene (Eagle et al, 1995) . No mutations were detectable, indicating that a yet unknown tumour suppressor gene on the distal chromosome lOq is involved in lung carcinogenesis. Mountain et al, 1991) .
MATERIALS AND METHODS

LOH analysis
Paired samples of tumour and normal DNA were assessed for allelic losses by microsatellite polymorphism analysis. Six different markers on chromosome lOq, i.e. DlOS169 (het. 0.73), D1OS677 (het. 0.81), DIOS1213 (het. 0.8), DlOS1223 (het. 0.74), DlOS1237 (het. 0.73) and DIOS212 (het. 0.71), were selected from the human genome marker screening set (Dubovsky et al, 1995) ; the cytogenetic localization and the relative genetic distances are shown in Figure 1 . Primer sequences were obtained from the genome database and commercially synthesized (MWG-Biotech, Ebersberg, Germany). Polymerase chain reaction (PCR) was performed with approximately 100 ng of DNA, 20 pmol of each primer and 200 gmol dNTPs. The DNA samples were denatured for 5 min and then amplified by 35 cycles (1 min at 95°C, 30 s at 550C and 30 s at 720C), followed by a final extension step of 5 min at 72°C. The annealing temperature was modified for the marker DIOS1213 and DIOS169 to 600C and for D1OS677 to 50°C. PCR products were checked on 1.5% agarose gels and then separated by 5% denaturing polyacrylamide gel electrophoresis (7 M urea/TBE). The DNA fragments were finally visualized by non-radioactive detection as previously described .
SSCP analysis
For mutational analysis of the MXI1 gene, the helix-loop-helix and the leucine-zipper exons were amplified (Eagle et al, 1995) . PCR conditions were modified (10 x buffer with magnesium chloride, 300 ng of template, 50 pmol each primer, 200 lmol dNTPs, annealing temperature 60°C). Aliquots of these PCR fragments were denatured and electrophoresed on a 5% non-denaturing polyacrylamide gel and detected non-radioactively . Sequencing PCR products were purified from a 1.5% agarose gel and sequenced by the dideoxy method using the Thermo Sequenase (Amersham, Buckinghamshire, UK) and an automated DNA sequencer (Licor-system purchased by MWG-Biotech).
Statistical analysis
Chi-square (x2) test was performed using the statistical software package NCSS supplied by Unisoft (Augsburg, Germany).
RESULTS
LOH analysis
Representative allelotype data from three cases are shown in Figure  1 . Patient no. 13 died from a SCLC whereas patients 28 and 39 suffered from a metastatic SCC. 
DISCUSSION
This study presents evidence that allelic loss on chromosome 10q is significantly associated with advanced stages in SCLC as well as tumour progression and metastases formation in SCC of the lung. Whereas in SCLC the histological diagnosis is generally predictive for the clinical course, which is characterized by extensive metastases formation, the histomorphological criteria of malignancy of NSCLC are far less reliable for the assessment of the clinical outcome than tumour staging (Nesbitt et al, 1995) . Allelotype studies of NSCLC indicated loss of genetic material on chromosome 10q in up to 27% of cases (Tsuchiya et al, 1992; Sato et al, 1994) , which correlates well with the overall percentage of 23% of LOH in the three subgroups of NSCLC in our study. Although one allelotype study showed a higher incidence of deletion in SCC than in adenocarcinomas, it failed to establish a significant correlation between LOH on chromosome 10q and clinicopathological parameters. This is probably because of the fact that a single RFLP marker was investigated per chromosomal arm, which reduced the number of informative cases per tumour subgroup. In addition, stage IV tumours were excluded from the statistical analysis (Sato et al, 1994) . We detected deletions preferentially in metastatic stage IV SCC, whereas non-metastatic SCC carried deletions only sporadically. The fact that we failed to identify deletions in adenocarcinomas and largecell carcinomas is probably because of the limited number of cases.
To The fact that some metastatic tumours did not show LOH is related to the limited number of polymorphisms investigated so far. The percentage of cases with LOH will probably increase with the number of additional markers and metastatic SCC may be of particular interest for the future refinement of the candidate region.
We observed a high incidence of allelic loss in the region between the markers D1OS677 and DIOS1223, which seems to harbour at least one tumour-suppressor gene. Although two nonoverlapping regions between the loci DIOS677/DlOS1237 and DIOS1213/DlOS1223 could be identified, the exact location and refinement of the minimal regions will need more markers and a larger sample size.
A similar result was found by a deletion mapping study of glial brain tumours: two gliomas showed interstital deletions that were located centromerically and were bracketed by the loci DIOS109 and DIOS206, whereas the majority carried deletions covering the distal part of the chromosome arm, with a non-overlapping region between the marker DIOS587 and DIOS216 (Rasheed et al, 1995) . These regions co-localize with the ones that we defined and are approximately mapped to chromosome bands lOq22 and lOq25. The comparison between the deletion pattems of gliomas and those of lung carcinomas is intriguing. Similar to glioblastomas, SCLC generally exhibit deletions of the entire chromosome or chromosomal arm (Levin et al, 1994; Ried et al, 1994; Petersen et al, 1997a) , whereas SCC and astrocytoma are more frequently characterized by interstitial deletions (Rasheed et al, 1995) . Both, astrocytoma and SCC may progress to glioblastoma and SCLC lOq loss in lung cancer 275 respectively (Churg et al, 1980; Kleihues et al, 1995) . Hypo thetically, the morphological and biological transition to the aggressive phenotype is mediated by a genetic alteration of chromosome lOq.
As shown in Table 2 the MXI1 gene has been mapped to the chromosomal band lOq24-q25 and is thus located centromerically to the markers DIOS169 and D1OS212. Although the physical and genetic distances of the adjacent markers to MXI1 are unknown, it is likely that the second region of LOH between the markers DIOS1223 and DIOS1213 coincides with the locus of the MXII gene. We failed to identify the mutations in two hotspot regions as reported in prostate cancer (Eagle et al, 1995) . The significance of this putative tumour-suppressor gene is unclear. To our knowledge, there are no further reports of mutations, and others have failed to confirm the findings in prostate cancer (Gray et al, 1995) .
Very recently, a new tumour-suppressor gene has been identified on chromosome lOq23, which was termed PTEN and MMAC1 by two groups who discovered the gene almost simultaneously (Li et al, 1997; Steck et al, 1997) . As it is mutated in advanced gliomas, breast and prostate carcinomas, it is an important candidate gene for late-stage lung carcinomas. In general, the functional role of angiogenesis inhibitor genes, which have been implicated in tumour progression and metastasis formation, is also consistent with the concept that a deletion is associated with the metastatic phenotype (Hanahan and Folkman, 1996) .
In summary, our data indicate that chromosome lOq harbours at least one tumour-suppressor gene that is associated with advanced tumour stage and metastastic phenotype in pulmonary SCC and SCLC. The usefulness of this lesion as a genetic marker for tumour progression and clinical outcome will be tested by future prospective studies. Hopefully, it will help clinicians and pathologists in the assessment of the malignant potential of human lung cancer. ABBREVIATIONS CGH, comparative genomic hybridization; LOH, loss of heterozygosity; MMAC1, mutated in multiple advanced cancers; MXI1, MAX interacting protein; NSCLC, non-small-cell lung carcinoma; SCLC, small-cell lung carcinoma; SCC, squamous cell carcinoma
